Companion diagnostics (CDx) are the tests or assays intended to
assist physicians in making effective treatment decisions based on
the patient response to the ongoing treatment with a targeted
therapeutic area. These tests are an indicative measure of the
patient sub-population that will be benefitted from the suggested
drug / therapy, and differentiates the non-responder patients from
the one’s who will respond to the treatment option. Hence, these
diagnostic tests ensure the commercialization of safer and efficient
targeted therapeutics with minimal or no side effects, while ensuring
economic benefits to pharmaceutical companies, and the patients as
well. Of late, many leading pharmaceutical companies are focusing on
regulating the costs incurred in the drug discovery, development and
commercialization process. This effort involves the development of
companion diagnostic along with a targeted therapeutic area, and this
has led to increasing collaborations between pharmaceutical and
medical device companies, to co-develop a drug with companion
diagnostic test. The tremendous research in the field of oncology,
has led to the discovery of numerous biomarkers facilitating disease
diagnosis and treatment, and these are some major factors
contributing to the increasing demand for personalized medicine, and
companion diagnostics tests in oncology.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4684
The market overview section of the report comprises qualitative
analysis of the overall companion diagnostic tests in oncology market
considering the factors determining the market dynamics such as
drivers, restraints and opportunities, along with Porter’s five
force analysis and market attractiveness analysis. In addition,
market opportunity analysis for detection techniques, biomarker, and
type of cancer, and key industry developments has also been provided.
Key industry developments include the major events occurred in past
decade and are expected to occur during the forecast period which are
likely to affect the market dynamics.
The global companion diagnostic tests in oncology market has been
segmented on the basis of detection technique, biomarker, cancer
type, and end-user. On the basis of detection technique, the global
companion diagnostic tests in oncology market is segmented into
protein detection technique, DNA detection technique, and other
detection techniques. The DNA detection techniques are further
segmented into polymerase chain reaction, next generation sequencing,
and in situ hybridization detection techniques. The biomarker segment
of the global companion diagnostic tests in oncology market is
segmented into EGFR, HER2, KRAS, BRAF V600E, and other biomarkers.
The cancer type segment of the global companion diagnostic tests in
oncology market is further segmented into breast cancer, lung cancer,
liver cancer, melanoma, colorectal cancer, and other cancers. The
end-user segment includes pharmaceutical & biotechnology
companies, medical device companies, research institutes, and other
end-users. The market for these detection techniques, biomarker,
cancer types and end users has been extensively analyzed on the basis
of factors such as incidence, prevalence of diseases, usage pattern
of detection techniques, sales revenue of the tests, geographic
presence of the market players and technological developments. The
market size and forecast in terms of revenue (US$ Mn) for each of
these segments have been provided for the period 2015 to 2025,
considering 2016 as the base year. The report also provides the
compounded annual growth rate (CAGR) for each segment for the
forecast period 2017 to 2025.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4684
Geographically, the companion diagnostic tests in oncology market has
been segmented into five regions namely; North America, Europe,
Asia-Pacific, Latin America, and the Middle East & Africa. The
market size and forecast for each region has been provided for the
period 2015 to 2025, in terms of detection techniques, biomarker,
cancer type, and end-user along with the CAGR (%) for the forecast
period 2017-2025.
The report also provides a section on the competitive landscape,
wherein the market share analysis of leading players in the global
companion diagnostic tests in oncology market, in terms of percentage
share in 2016 has been discussed. A list of recommendations has also
been included for new entrants as well as existing market players to
help them establish a strong presence in the market and increase
their market share. The report concludes with the profiles of major
players in the global Companion Diagnostic Tests in Oncology market
such as F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott,
Agilent Technologies, Inc., Genomic Health, Inc., bioMerieux SA,
BioGenex, AGENDIA NV, Siemens Healthcare GmBH, and Thermo Fisher
Scientific, Inc., among others. The major market players are
evaluated on various parameters such as company overview, financial
overview, product portfolio, business strategies and recent
developments.
Request a Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4684
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment